[Fully bioresorbable drug-eluting coronaryscaffolds: A review]

Comite dĀ“Evaluation et de Diffusion des Innovations Technologiques (CEDIT)
Record ID 32015001191
Authors' objectives: Following the development of stents, then drug-eluting stents (DES), bioresorbable scaffolds are proposed as a third evolution in coronary angioplasty, aiming to reduce the incidence of restenosis and stent thrombosis and to restore vascular physiology. At least 16 such devices are currently under development, but published clinical data were available for only three of them in September 2014.
Authors' recomendations: The available results suggest that the technological and clinical development of bioresorbable scaffolds is not yet complete: their possible clinical benefits are still unclear compared with third-generation DES; the impact of arterial physiology restoration has to be assessed over the long term; and their cost-effectiveness has to be established. From the perspective of a health technology assessment, there is no compelling reason to hasten the clinical use of these devices before the results of ongoing randomized controlled trials become available.
Project Status: Completed
Year Published: 2015
English language abstract: An English language summary is available
Publication Type: Not Assigned
MeSH Terms
  • Humans
  • Absorbable Implants
  • Drug-Eluting Stents
  • Technology Assessment, Biomedical
Organisation Name: Cellule Innovation of the AP-HP
Copyright: Comite dĀ“Evaluation et de Diffusion des Innovations Technologiques (CEDIT)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.